The trend is to start treatment as early as possible and that means that CIS subgroup within the MS market should grow. I don't know how much of Copaxone's sales come from CIS subgroup but I assume that since both Avonex and Betaseron are approved to treat a first clinical episode with MRI findings consistent with MS, Copaxone should gain share at their expense. I haven't seen graphs but have read the info about conversions in a recent clinical review.
Market Data 
Markets 
AI
